EphA2 Kinase (Human) Assay/Inhibitor Screening Assay Kit
Cat.No. : | Kit-0326 |
Product Overview : | EphA2 Kinase (Human) Assay/Inhibitor Screening Assay Kit is a single-site, non-quantitative immunoassay for kinase activity of recombinant catalytic domain of EphA2 kinase. Plates are pre-coated with a newly designed "Tyrosine kinase-substrate-1", which can be easily phosphorylated by recombinant catalytic domain of EphA2 kinase. The detector antibody is PY-39, an antibody that specifically detects the phosphotyrosine residue on "Tyrosine kinase-substrate-1". |
- Specification
- Gene Information
- Related Products
Applications : | 1) Screening inhibitors or activators of recombinant catalytic domain of EphA2 Kinase.2) Detecting the effects of pharmacological agents on recombinant catalytic domain of EphA2 Kinase. |
Storage : | Upon receipt store all other components at 4°C; Do not expose reagents to excessive light |
Products Types
◆ Recombinant Protein | ||
Epha2-954M | Recombinant Mouse Epha2 Protein, MYC/DDK-tagged | +Inquiry |
Epha2-915MB | Recombinant Mouse Epha2 protein(Met1-Asn535), His & Avi-tagged, Biotinylated | +Inquiry |
EPHA2-27H | Active Recombinant Human EPHA2 Protein (Gln25-Asn534), C-6×His tagged | +Inquiry |
Epha2-38M | Recombinant Mouse Epha2 Protein, His (Fc)-Avi-tagged | +Inquiry |
EPHA2-0986H | Recombinant Human EPHA2 Protein (R561-I976), GST tagged | +Inquiry |
◆ Lysates | ||
EPHA2-2138MCL | Recombinant Mouse EPHA2 cell lysate | +Inquiry |
EPHA2-001HCL | Recombinant Human EPHA2 cell lysate | +Inquiry |
EPHA2-1072HCL | Recombinant Human EPHA2 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionTherapeutic strategies for EPHA2 include inhibition of its expression, blocking its signal transduction pathway, and modulating its interaction with ligands. These strategies may involve the use of small molecule inhibitors, antibodies, or other types of therapeutics.
The expression level of EPHA2 is associated with the occurrence and progression of a variety of diseases. For example, in tumors such as lung, breast, and colorectal cancer, EPHA2 expression levels may be elevated and correlated with the degree of malignancy and poor prognosis of the tumor.
In some tumors, EPHA2 expression levels are associated with poor prognosis in patients. For example, patients with lung cancer who express EPHA2 often have shorter survival. Therefore, the expression level of EPHA2 may be one of the indicators to predict tumor prognosis.
Some diseases can be diagnosed by measuring EPHA2 expression levels, such as immunohistochemistry, western blotting, and real-time PCR.
Yes, EPHA2 can be used as a target for the treatment of certain diseases. For example, inhibition of EPHA2 expression can inhibit tumor growth and spread, so EPHA2 can serve as a potential therapeutic target. In addition, regulating the expression level of EPHA2 may also be helpful in the treatment of diseases such as the nervous system and cardiovascular system.
EPHA2 can promote cancer metastasis and affect the spread and spread of cancer by regulating processes such as invasion and migration of tumor cells. Therefore, inhibition of EPHA2 expression or blocking its signal transduction pathway may have a potential therapeutic effect on inhibiting cancer metastasis.
Customer Reviews (3)
Write a reviewThe protein has low cytotoxicity.
EPHA2 has good stability, and the test results of heat resistance, acid and alkali resistance and protease degradation resistance are good.
Kinetic parameters such as enzymatic reaction rate and binding affinity were tested, and the protein performed well.
Ask a Question for All EphA2 Products
Required fields are marked with *
My Review for All EphA2 Products
Required fields are marked with *
Inquiry Basket